<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2147">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563650</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0079</org_study_id>
    <nct_id>NCT04563650</nct_id>
  </id_info>
  <brief_title>COVID-19 Serology and Immunosenescence</brief_title>
  <acronym>SERO-CoV-OLD</acronym>
  <official_title>Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an
      elderly institutionalized population presenting fragility factors.

      This study also aims to stratify seroconversion by immunological profiles of the elderly
      patients residing in the EHPAD. This stratification requires the measurement of immunological
      marker levels already described in immunosenescence and also involved in the development of
      certain chronic infectious diseases more common in the elderly population. This analysis will
      enable the investigators to describe an immunological, clinical and biological profile
      representing a patient who has developed an immunity against COVID 19. It will also help the
      investigators to understand the different mechanisms leading to a reduced immune response
      after a potential administration of a vaccine. Finally, it will help describe the immune
      profiles of elderly residents who presented with non-severe forms of COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>titers of COVID-19 neutralising antibodies</measure>
    <time_frame>day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>titers of COVID-19 neutralising antibodies</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>titers of COVID-19 neutralising antibodies</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>titers of COVID-19 neutralising antibodies</measure>
    <time_frame>at 9 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Covid19</condition>
  <condition>Geriatric Medicine</condition>
  <condition>Seroconversion</condition>
  <condition>Immunosenescence</condition>
  <arm_group>
    <arm_group_label>COVID-19 positive resident</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 negative resident</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.</description>
    <arm_group_label>COVID-19 negative resident</arm_group_label>
    <arm_group_label>COVID-19 positive resident</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Residents of the EHPAD/USLD St Victor of the Amiens CHU who took part in the screening
             campaign (RT-PCR and serology) organized by the Amiens CHU

          -  residents who signed a consent form to participate in the study

        Exclusion Criteria:

          -  The patient or his legal representative refused to participate in the study

          -  Heavily sedated patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julien MOYET, MD</last_name>
    <phone>03.22.08.95.41</phone>
    <email>moyet.julien@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien MOYET Julien, MD</last_name>
      <phone>03.22.08.95.41</phone>
      <email>moyet.julien@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric JOSEPH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Philippe LANOIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric BLOCH, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne BROCHOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>geriatric medicine</keyword>
  <keyword>seroconversion</keyword>
  <keyword>immunosenescence</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

